PTC Therapeutics, Inc.

337 articles with PTC Therapeutics, Inc.

• PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference

  1/7/2019

  Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually

• PTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house

  1/7/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical Operations Officer.

• PTC Therapeutics to Participate at Upcoming January 2019 Investor Conference

  1/2/2019

  PTC Therapeutics, Inc. today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, January 8th at 5 p.m. PST.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on December 17, 2018

  12/20/2018

  PTC Therapeutics, Inc. today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees.  

• PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments

  12/18/2018

  Ms. Okey brings decades of experience launching and commercializing rare and orphan disease products.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on December 4, 2018

  12/7/2018

  PTC Therapeutics, Inc. today announced that on December 4, 2018 it approved non-statutory stock options to purchase an aggregate of 48,750 shares of its common stock to 10 new employees.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on November 13, 2018

  11/16/2018

  PTC Therapeutics, Inc. today announced that on November 13, 2018 it approved non-statutory stock options to purchase an aggregate of 75,200 shares of its common stock to 19 new employees.

• PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update

  11/5/2018

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2018.

• PTC Therapeutics to Participate at Upcoming November 2018 Investor Conference

  10/30/2018

   PTC Therapeutics, Inc. today announced that management will present a company overview at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13th at 10:55 a.m. MST.  

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on October 17, 2018

  10/23/2018

  PTC Therapeutics, Inc. today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees.  

• PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results

  10/22/2018

  PTC Therapeutics, Inc. today announced that the Company will host a webcast conference call to report its third quarter 2018 financial results and provide an update on the company's business and outlook on Monday, November 5, 2018 at 4:30 p.m. (ET) after closing of the market.

• PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation

  10/6/2018

  Analysis of data to date shows Translarna Preserved Ambulation for up to 5 Years Compared to Natural History

• Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

  10/3/2018

  Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones

• 

  PTC Therapeutics' Drug for Spinal Muscular Atrophy Shows Promise in 2 Trials

  10/3/2018

  PTC Therapeutics announced interim data from Part 1 of its open-label clinical trials, FIREFISH and SUNFISH, of risdiplam for Type 1, 2 and 3 spinal muscular atrophy in collaboration with Genentech.
• 

  Arix Bioscience Leads $58 Million Series A into VelosBio, Taking 11.2% Stake

  10/1/2018

  VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on September 25, 2018

  9/28/2018

  PTC Therapeutics, Inc. today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.  

• PTC Therapeutics to Participate at Upcoming October 2018 Investor Conference

  9/25/2018

  PTC Therapeutics, Inc. today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9th at 2:00 p.m. EST.

• 

  BioSpace Movers and Shakers Sept. 24

  9/24/2018

  Here's a look at who's making moves in the biotech and pharma world this week.

• PTC Therapeutics to Participate at Upcoming Investor Conference on September 27 2018

  9/13/2018

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27th at 1:30 p.m. EST.

• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.